Curr Health Sci J, vol. 46, no. 3, 2020

Strong Long-Term Survival with Targeted Therapy in Inoperable/Metastatic Gastrointestinal Stromal Tumors

[Case Report]

C. TUTA(1), B.I. VATU(2), S.A. ARTENE(3)

(1)Emergency County Hospital of Alexandria, Romania,
(2)Emergency County Hospital of Slatina, Romania,
(3)Department of Biochemistry, University of Medicine and Pharmacy of Craiova, Romania


Gastrointestinal stromal tumors (GISTs) belong to a group of cancers called soft-tissue sarcomas. Soft-tissue sarcomas develop in the tissues that support and connect the body, including muscles, nerves, tendons and joints. In this paper we report a case of 67-years old man with unresectable GIST and associated liver metastasis who experienced a very good response to Imatinib mesylate (GlivecĀ®) therapy in first line for over 10 years. Even after progression and discovery of liver metastasis, increasing the GlivecĀ® dose proved to be an efficient strategy with no added toxicity and an overall satisfactory quality of life.

GIST, Imatinib, targeted therapy, metastasis.

Cristian Tuta, Emergency County Hospital of Alexandria, Romania, e-mail:

DOI 10.12865/CHSJ.46.03.16 - Download PDF